Adding ribociclib (Kisqali) to a nonsteroidal aromatase inhibitor (NSAI) produced an overall survival (OS) benefit vs NSAI ...
Briganti and colleagues concluded that, together with the main PROTEUS study, the substudy supports 1-year perioperative apalutamide plus ADT as a treatment option for patients with high-risk ...
Adding pembrolizumab to carboplatin and etoposide improved response rates and OS vs chemotherapy alone in metastatic NEPC in ...
In October 2026, the Vatican announced that Pope Leo XIV had undergone a right lower lobectomy to remove a lung nodule that ...
Oana Danciu, MD, explained why phase 1 breast cancer trials are moving earlier in the treatment course and how disease ...
Subgroup analyses of the phase 3 RASolute 302 trial showed overall survival favored daraxonrasib over chemotherapy in metastatic pancreatic cancer. Six-year NATALEE data show ribociclib plus an NSAI ...
Findings from the AZUR-1 trial support the FDA approval of dostarlimab for patients with stage II/III locally advanced rectal ...
Sofetabart mipitecan (Sofe-M), an investigational folate receptor α (FRα)–directed antibody-drug conjugate (ADC), yielded ...
The FDA assigned a PDUFA date of June 14, 2027, to UGN-103, for the treatment of recurrent low-grade intermediate-risk ...
Erik Bengtsen, MD, discussed meaning-centered therapy at the bedside, framing psychiatry referrals, and a more humanistic ...
Investigators will share detailed findings from the phase 1a/b EMBOLD PanTumour-101 study at the European Society for Medical ...
Matthew J. Frigault, MD, and Adam D. Cohen, MD, outline how updated NCCN guidelines position CAR T-cell therapy in early ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results